Synageva BioPharma Corp

Synageva BioPharma — Merger or Acquisition (May 2015)

20 slides from Synageva BioPharma's merger presentation, May 6, 2015

  1. Slide 1: Alexion: Global Leader in Rare Diseases

    Alexion: Global Leader in Rare Diseases Filed by Alexion Pharmaceuticals, , Inc. Pursuant to Rule 425 Under the Securities Act of 1933 and deemed filed pursuant to Rule 14d - 2 of the Securities Exchange Act of 1934 Subject Company: Synageva BioPharma Corp. Commission File No.: 0 - 23155

  2. Slide 2: Forward-looking statements

    2 This communication includes statements that may be forward - looking statements. The words “believe,” “expect,” “anticipate,” “pr oject” and similar expressions, among others, generally identify forward - looking statements. Alexion and Synageva caution that these forward - looking statements are

  3. Slide 3: Additional information about the transaction

    3 Offeror plans to file a tender offer statement on Schedule TO, together with other related exchange offer documents, includin g a letter of transmittal, in connection with the offer; Synageva plans to file a Solicitation/Recommendation Statement on Schedule 14D - 9 in connection with the offer; an

  4. Slide 4: Our Exclusive Focus: Treating Patients with Devastating and Rare Diseases

    4 Our Exclusive Focus : Treating Patients with Devastating and Rare Diseases Alexion is focused on developing life - transforming treatments for patients with devastating and rare diseases 4 Severe Life - Threatening No Effective Treatments Transformative Clinical Benefit Devastating

  5. Slide 5: Alexion: Global Leader in Rare Diseases

    5 Alexion: Global Leader in Rare Diseases • Kanuma ( sebelipase alfa) for LAL Deficiency aligns with our exclusive focus on bringing transformative therapies to patients suffering from under - diagnosed , devastating and rare diseases, such as PNH, aHUS and HPP Exclusive Focus on Life - Transforming

  6. Slide 6: Transaction Details

    6 Transaction Details • Total consideration of approximately $230 per share, based on the 9 day volume - weighted average closing price of Alexion stock through May 5, 2015 ▪ $ 115.00 in cash and 0.6581 shares of Alexion common stock for each Synageva share ▪ Total stock issuance of 26.2 million sha

  7. Slide 7: Synageva BioPharma: Ideal Strategic and Operational Fit

    7 Synageva BioPharma: Ideal Strategic and Operational Fit • Patient - centric culture • Focus on discovering, developing and delivering medicines for patients with rare and devastating diseases Exclusive Focus on Rare Diseases • Kanuma under review for the treatment of patients with LAL Deficiency •

  8. Slide 8: Synageva's Pipeline to Strengthen and Broaden Alexion's Portfolio

    8 Synageva’s Pipeline to Strengthen and Broaden Alexion’s Clinical and Preclinical Portfolio Source: Synageva Investor Presentation, April 2015 • Pipeline of rare disease assets • Highly innovative late - stage product, Kanuma (sebelipase alfa) • Expression platform to develop novel and next generat

  9. Slide 9: Understanding Devastating Diseases: LAL Deficiency

    9 • Caused by mutations affecting the LIPA gene resulting in a deficiency of lysosomal acid lipase (LAL) activity • Characterized by the accumulation of cholesteryl esters and triglycerides in lysosomes in cells throughout the body leading to severe complications including fibrosis, cirrhosis, liver

  10. Slide 10: LAL Deficiency is an Ideal Fit for Alexion's Exclusive Focus

    10 LAL - D is an Ideal Fit for Alexion’s Exclusive Focus on Treating Patients with Devastating and Rare Diseases Sources: Hillmen P, Lewis SM, Bessler M et al. N Engl J Med. 1995; 333:1253 - 1258; Caprioli, J., et al. Blood. 2006; 108:1267 - 12 79; Whyte et al. Poster presented at the 2014 PAS Meeti

  11. Slide 11: Kanuma: An Investigational Treatment for LAL Deficiency

    11 Kanuma: An Investigational Treatment for Patients Suffering From LAL - D • ALT Normalization » 31% of sebelipase alfa patients vs. 7% of placebo patients (p=0.027) • AST Normalization » 42% of sebelipase alfa patients vs. 3% of placebo patients (p<0.001) • Relative R eduction in LDL - C » Mean re

  12. Slide 12: Kanuma Aligned with Alexion's Portfolio of Life-Transforming Therapies

    12 Kanuma, an Investigational Treatment for LAL - D, is Aligned with Alexion’s Portfolio of Life - Transforming Therapies Sources: Hill A et al. Presented at the Annual ASH Meeting December, 2012; Johnson et al. Presented at ERA - EDTA Congress , May, 2014; Licht C et al. ASH 2012. Poster 985; Whyte

  13. Slide 13: Alexion's Proven Track Record in Identifying Patients with Rare Diseases

    13 Alexion’s Proven Track Record in Identifying Patients with Underdiagnosed, Devastating and Rare Diseases PNH Annual Newly Identified PNH Patients in Core Markets Alexion’s PNH diagnostic initiatives have enabled the company to identify a similar number of new PNH patients annually since the Solir

  14. Slide 14: Diagnostic Expertise Leveraged for HPP and Patient Identification

    14 Alexion’s PNH and aHUS Diagnostic Expertise will be Leveraged for Our HPP and LAL - D Patient Identification Initiatives PNH aHUS HPP LAL - D Driving Diagnosis Across Multiple Rare Diseases Soliris for PNH Soliris for aHUS Hematology & Nephrology Franchise Strensiq for HPP Kanuma for LAL - D Meta

  15. Slide 15: Alexion to Maximize Synageva's Value Across 50-Country Platform

    15 Alexion to Maximize Synageva’s Value, Leveraging Our Expertise Across Our 50 - Country Platform • Leverage our 50 - country platform and expand Alexion’s metabolic franchise to launch Kanuma • Utilize Alexion’s global regulatory expertise to secure approvals in all key markets • Secure worldwide

  16. Slide 16: Kanuma will Further Accelerate and Diversify Revenues

    16 Following Approval, Kanuma w ill Further Accelerate and Diversify Our Strong, Consistently Growing Revenues Across Our 50 - Country Platform Revenues in 2016 – 2020 are illustrative and should not be taken as guidance * $2,1465M excludes ~$88M in prior years’ sales in France ; ‡ Midpoint of FY15

  17. Slide 17: Metabolic Franchise: Anticipated Launches in 2015

    17 METABOLIC FRANCHISE Anticipated Launches in 2015 PRECLINICAL CLINICAL DEVELOPMENT REGISTRATION FILINGS Alexion Program Synageva Program cPMP MoCD Type A Strensiq HPP Asfotase Alfa NF - 1 SBC - 105 GACI/Other Undisclosed Preclinical #6 SBC - 103 MPSIIIB mRNA Therapies #1 Kanuma LAL - D Undisclosed

  18. Slide 18: Creating the Most Robust Rare Disease Pipeline in Biotech

    18 Creating the Most Robust Rare Disease Pipeline in Biotech PRECLINICAL EARLY CLINICAL DEVELOPMENT ADVANCED CLINICAL DEVELOPMENT REGISTRATION FILINGS MARKETED Soliris Next Gen Inflammatory Metabolic Undisclosed Synageva Complement Inhibition Soliris DGF ALXN1007 APS Complement Inhibitor (4) ALXN550

  19. Slide 19: Alexion: Global Leader in Rare Diseases

    19 • Strengthens Alexion’s global leadership in developing and commercializing therapies for patients with devastating and rare diseases • Expands Alexion’s metabolic franchise with the addition of Kanuma for patients with LAL - D • Launches of Kanuma and Strensiq expected in 2015 • Creates the most

  20. Slide 20: BioPharma

    BioPharma

Synageva Biopharma — Merger or Acquisition (May 2015) on 6ix